(Q36376607)

13 August 2017

title

An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

Min Kong

1

1 reference

13 August 2017

Maowen Ba

2

1 reference

13 August 2017

Chao Ren

3

1 reference

13 August 2017

Ling Yu

4

1 reference

13 August 2017

Shengjie Dong

5

1 reference

13 August 2017

Guoping Yu

6

1 reference

13 August 2017

Hui Liang

7

1 reference

13 August 2017

language of work or name

English

0 references

publication date

5 May 2017

1 reference

13 August 2017

1 reference

Basal Ganglia Circuits as Targets for Neuromodulation in Parkinson Disease

13 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Which dyskinesia scale best detects treatment response?

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Synaptic dysfunction in Parkinson's disease.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Levodopa-induced dyskinesias

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Amantadine for dyskinesia in Parkinson's disease

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET - [(11)C]raclopride study

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Amantadine for dyskinesia in patients affected by severe Parkinson's disease.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5593643

Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28915672

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28915672

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28915672

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.17622

1 reference

13 August 2017

0 references